Is Kyverna Therapeutics, Inc. (KYTX) a Buy, Sell, or Hold?
NASDAQ : KYTX
Kyverna Therapeutics, Inc.
$7.78 USD
-$0.16 (-2.02%)
- Volume
- 1.25M
- Average Volume
- 1.19M
- Market Capitalization
- $340.7M
- P/E Ratio
- -2.37
- Dividend Yield
- 0.00%
- Price Target
- $25.00
- Year High
- $13.67
- Year Low
- $2.80
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.15
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
41
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
4
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$502.19K
KYTX Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
KYTX Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| CLARK IAN T | director | 2026-05-27 | A-Award | 0 | 2026-05-29 |
| CLARK IAN T | director | 2026-05-27 | A-Award | 8.59 | 2026-05-29 |
| Cohen Fred E | director | 2026-05-27 | A-Award | 0 | 2026-05-29 |
| Cohen Fred E | director | 2026-05-27 | A-Award | 8.59 | 2026-05-29 |
| SEIDENBERG BETH C | director | 2026-05-27 | A-Award | 0 | 2026-05-29 |
| SEIDENBERG BETH C | director | 2026-05-27 | A-Award | 8.59 | 2026-05-29 |
| Shaw Christi | director, officer: Executive Chairperson | 2026-05-27 | F-InKind | 8.59 | 2026-05-29 |
| Aktar Mert | director | 2026-05-27 | A-Award | 0 | 2026-05-29 |
| Aktar Mert | director | 2026-05-27 | A-Award | 8.59 | 2026-05-29 |
| Martini Gregory S. | officer: Chief Financial Officer | 2026-05-18 | A-Award | 8.54 | 2026-05-20 |
| Martini Gregory S. | 2026-05-18 | 0 | 2026-05-20 | ||
| Dac Nadia | officer: Chief Commercial Officer | 2026-05-04 | A-Award | 9 | 2026-05-06 |
| Dac Nadia | 2026-05-04 | 0 | 2026-05-06 | ||
| GRASSO MARC | officer: Chief Financial Officer | 2026-03-13 | A-Award | 8.95 | 2026-03-17 |
| GRASSO MARC | officer: Chief Financial Officer | 2026-03-13 | A-Award | 0 | 2026-03-17 |
| Biddle Warner Weston | director, officer: Chief Executive Officer | 2026-03-13 | A-Award | 8.95 | 2026-03-17 |
| Biddle Warner Weston | director, officer: Chief Executive Officer | 2026-03-13 | A-Award | 0 | 2026-03-17 |
| GEHCHAN NAJI | officer: See Remarks | 2026-03-13 | A-Award | 8.95 | 2026-03-17 |
| GEHCHAN NAJI | officer: See Remarks | 2026-03-13 | A-Award | 0 | 2026-03-17 |
| Miller Andrew Craig | 2026-02-24 | 0 | 2026-03-04 | ||
| Miller Andrew Craig | director | 2026-02-24 | A-Award | 7.95 | 2026-03-04 |
| Miller Andrew Craig | director | 2026-02-24 | A-Award | 0 | 2026-03-04 |
| Emany Sravan Kumar | director | 2026-02-24 | A-Award | 7.95 | 2026-02-26 |
| Emany Sravan Kumar | director | 2026-02-24 | A-Award | 0 | 2026-02-26 |
| Emany Sravan Kumar | 2026-02-24 | 0 | 2026-02-26 | ||
| Pujols Mayobanex | 2026-02-09 | 0 | 2026-02-11 | ||
| Pujols Mayobanex | officer: Chief Technology Officer | 2026-02-09 | A-Award | 8.08 | 2026-02-11 |
| Shaw Christi | director, officer: Executive Chairperson | 2026-01-12 | A-Award | 8.23 | 2026-01-14 |
| Shaw Christi | director, officer: Executive Chairperson | 2026-01-12 | A-Award | 0 | 2026-01-14 |
| Shaw Christi | director, officer: Executive Chairperson | 2026-01-12 | A-Award | 0 | 2026-01-14 |
| SEIDENBERG BETH C | director | 2025-12-18 | P-Purchase | 7.5 | 2025-12-22 |
| Westlake BioPartners Opportunity Fund I, L.P. | 10 percent owner | 2025-12-18 | P-Purchase | 7.5 | 2025-12-22 |
| Walker Karen Marie | officer: Chief Technology Officer | 2025-12-15 | M-Exempt | 4.83 | 2025-12-17 |
| Walker Karen Marie | officer: Chief Technology Officer | 2025-12-15 | M-Exempt | 4.83 | 2025-12-17 |
| Walker Karen Marie | officer: Chief Technology Officer | 2025-12-15 | S-Sale | 12.2 | 2025-12-17 |
| GRASSO MARC | officer: Chief Financial Officer | 2025-06-30 | A-Award | 3.07 | 2025-07-01 |
| GRASSO MARC | 2025-06-30 | 0 | 2025-07-01 | ||
| Shaw Christi | director | 2025-05-29 | A-Award | 2.63 | 2025-06-02 |
| Shaw Christi | director | 2025-05-29 | A-Award | 0 | 2025-06-02 |
| SEIDENBERG BETH C | director, 10 percent owner: | 2025-05-29 | A-Award | 2.63 | 2025-06-02 |
| SEIDENBERG BETH C | director, 10 percent owner: | 2025-05-29 | A-Award | 0 | 2025-06-02 |
| SPIEGELMAN DANIEL K | director | 2025-05-29 | A-Award | 2.63 | 2025-06-02 |
| SPIEGELMAN DANIEL K | director | 2025-05-29 | A-Award | 0 | 2025-06-02 |
| Aktar Mert | director | 2025-05-29 | A-Award | 2.63 | 2025-06-02 |
| Aktar Mert | director | 2025-05-29 | A-Award | 0 | 2025-06-02 |
| CLARK IAN T | director | 2025-05-29 | A-Award | 2.63 | 2025-06-02 |
| CLARK IAN T | director | 2025-05-29 | A-Award | 0 | 2025-06-02 |
| Cohen Fred E | director, 10 percent owner: | 2025-05-29 | A-Award | 2.63 | 2025-06-02 |
| Cohen Fred E | director, 10 percent owner: | 2025-05-29 | A-Award | 0 | 2025-06-02 |
| Biddle Warner Weston | director, officer: Chief Executive Officer | 2024-04-11 | A-Award | 2.06 | 2025-04-15 |
| Jones Ryan Alexander | officer: Chief Financial Officer | 2024-04-11 | A-Award | 2.06 | 2025-04-15 |
| Jones Ryan Alexander | officer: Chief Financial Officer | 2025-04-11 | A-Award | 0 | 2025-04-15 |
| Walker Karen Marie | officer: Chief Technology Officer | 2024-04-11 | A-Award | 2.06 | 2025-04-15 |
| Walker Karen Marie | officer: Chief Technology Officer | 2025-04-11 | A-Award | 0 | 2025-04-15 |
| Shaw Christi | director | 2025-02-14 | A-Award | 3.03 | 2025-02-19 |
| GEHCHAN NAJI | officer: See Remarks | 2025-01-22 | A-Award | 3.29 | 2025-01-24 |
| GEHCHAN NAJI | 2025-01-22 | 0 | 2025-01-24 | ||
| Aktar Mert | director | 2024-10-21 | A-Award | 5.2 | 2024-10-24 |
| Aktar Mert | 2024-10-21 | 0 | 2024-10-24 | ||
| Biddle Warner Weston | director, officer: Chief Executive Officer | 2024-09-16 | A-Award | 6.89 | 2024-09-18 |
| Shaw Christi | director | 2024-09-16 | A-Award | 6.89 | 2024-09-18 |
| Biddle Warner Weston | 2024-09-16 | 0 | 2024-09-18 | ||
| Shaw Christi | 2024-09-16 | 0 | 2024-09-18 | ||
| GILEAD SCIENCES, INC. | 10 percent owner | 2024-02-12 | P-Purchase | 22 | 2024-02-13 |
| GILEAD SCIENCES, INC. | 10 percent owner | 2024-02-12 | C-Conversion | 0 | 2024-02-13 |
| GILEAD SCIENCES, INC. | 10 percent owner | 2024-02-12 | C-Conversion | 0 | 2024-02-13 |
| GILEAD SCIENCES, INC. | 10 percent owner | 2024-02-12 | C-Conversion | 0 | 2024-02-13 |
| CLARK IAN T | director | 2024-02-07 | 4.42 | 2024-02-07 | |
| CLARK IAN T | director | 2024-02-07 | 4.83 | 2024-02-07 | |
| Kotzin Brian L. | director | 2024-02-07 | 4.83 | 2024-02-07 | |
| Kotzin Brian L. | director | 2022-08-28 | 0.32 | 2024-02-07 | |
| Maag Peter | director, officer: Chief Executive Officer | 2024-02-07 | 0 | 2024-02-07 | |
| Maag Peter | director, officer: Chief Executive Officer | 2024-02-07 | 0 | 2024-02-07 | |
| Maag Peter | director, officer: Chief Executive Officer | 2024-02-07 | 4.33 | 2024-02-07 | |
| Maag Peter | director, officer: Chief Executive Officer | 2024-02-07 | 4.83 | 2024-02-07 | |
| Maag Peter | director, officer: Chief Executive Officer | 2024-02-07 | 3.15 | 2024-02-07 | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2024-02-07 | 0 | 2024-02-07 | |
| GILEAD SCIENCES, INC. | 10 percent owner | 2024-02-07 | 0 | 2024-02-07 | |
| GILEAD SCIENCES, INC. | 10 percent owner | 2024-02-07 | 0 | 2024-02-07 |